Literature DB >> 11036942

SH2-B and SIRP: JAK2 binding proteins that modulate the actions of growth hormone.

C Carter-Su1, L Rui, M R Stofega.   

Abstract

Growth hormone (GH) has long been known to be a primary determinant of body height and an important regulator of body metabolism, yet the cellular and molecular bases for these effects of GH are only beginning to be understood. In 1993, GH receptor (GHR) was first observed to bind to the tyrosine kinase JAK2. GH increased JAK2's affinity for GHR, potently activated JAK2, and stimulated the phosphorylation of tyrosines within JAK2 and the cytoplasmic domain of GHR. In the intervening six years, a variety of signaling molecules have been identified that are tyrosyl phosphorylated in response to GH, presumably by the activated JAK2. These signaling molecules include 1) the latent cytoplasmic transcription factors--designated signal transducers and activators of transcription (Stats)--that have been implicated in the regulation of a variety of GH-dependent genes; 2) Shc proteins that lead to activation of the Ras-MAP kinase pathway: and 3) insulin receptor substrate (IRS) proteins that bind and thereby activate phosphatidylinositol 3' kinase and presumably other proteins. Recently, we have identified two additional signaling molecules for GH that bind to JAK2 and are phosphorylated on tyrosines in response to GH: SH2-B and signal regulated protein (SIRP). Based upon amino acid sequence analysis, SH2-B is presumed to be a cytoplasmic adapter protein. It binds with high affinity via its SH2 domain to phosphorylated tyrosines within JAK2. GH-induced binding of SH2-B to JAK2 via this site potently activates JAK2, leading to enhanced tyrosyl phosphorylation of Stat proteins and other cellular proteins. Because of its other potential protein-protein interaction domains and its recruitment and phosphorylation by kinases that are not activated by SH2-B, SH2-B is thought likely to mediate other, more-specific actions of GH, as yet to be determined. SIRP is a transmembrane protein that is now known to bind to integrin-associated protein. It appears to bind directly to JAK2 by a process that does not require tyrosyl phosphorylation, although is itself highly phosphorylated on tyrosines in response to GH. The phosphorylated SIRP recruits one or more molecules of the tyrosine phosphatase SHP2 that, in turn, de-phosphorylates SIRP and most likely JAK2. Thus, SIRP is predicted to be a negative regulator of GH action. It seems likely that the diverse actions of GH will be found to require coordinated interaction of all of these signaling proteins with each other as well as with other signaling molecules that are activated by GH and the numerous other ligands that are present at cells during a response to GH.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11036942

Source DB:  PubMed          Journal:  Recent Prog Horm Res        ISSN: 0079-9963


  7 in total

Review 1.  Suppressors of cytokine signaling in health and disease.

Authors:  Jane C Tan; Ralph Rabkin
Journal:  Pediatr Nephrol       Date:  2005-02-19       Impact factor: 3.714

2.  Impaired JAK-STAT signal transduction contributes to growth hormone resistance in chronic uremia.

Authors:  F Schaefer; Y Chen; T Tsao; P Nouri; R Rabkin
Journal:  J Clin Invest       Date:  2001-08       Impact factor: 14.808

3.  Identification, cDNA cloning, and targeted deletion of p70, a novel, ubiquitously expressed SH3 domain-containing protein.

Authors:  Nick Carpino; Ryuji Kobayashi; Heesuk Zang; Yutaka Takahashi; Shiann-Tarrng Jou; Jian Feng; Hideaki Nakajima; James N Ihle
Journal:  Mol Cell Biol       Date:  2002-11       Impact factor: 4.272

4.  SH2-B is required for both male and female reproduction.

Authors:  Satoshi Ohtsuka; Satoshi Takaki; Masanori Iseki; Kanta Miyoshi; Naomi Nakagata; Yuki Kataoka; Nobuaki Yoshida; Kiyoshi Takatsu; Akihiko Yoshimura
Journal:  Mol Cell Biol       Date:  2002-05       Impact factor: 4.272

5.  Prolactin receptor-integrin cross-talk mediated by SIRPα in breast cancer cells.

Authors:  Traci Galbaugh; Yvonne B Feeney; Charles V Clevenger
Journal:  Mol Cancer Res       Date:  2010-09-08       Impact factor: 5.852

6.  Identification of growth hormone receptor in localised neurofibromas of patients with neurofibromatosis type 1.

Authors:  K S G Cunha; E P Barboza; E C Da Fonseca
Journal:  J Clin Pathol       Date:  2003-10       Impact factor: 3.411

7.  Identification of growth hormone receptor in plexiform neurofibromas of patients with neurofibromatosis type 1.

Authors:  Karin Soares Gonçalves Cunha; Eliane Porto Barboza; Eliene Carvalho da Fonseca
Journal:  Clinics (Sao Paulo)       Date:  2008-02       Impact factor: 2.365

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.